Your browser doesn't support javascript.
loading
TAVR in TAVR: Where Are We in 2023 for Management of Failed TAVR Valves?
Meier, David; Tzimas, Georgios; Akodad, Mariama; Fournier, Stephane; Leipsic, Jonathon A; Blanke, Philipp; Wood, David A; Sellers, Stephanie L; Webb, John G; Sathananthan, Janarthanan.
Affiliation
  • Meier D; Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Tzimas G; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, Canada.
  • Akodad M; Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Fournier S; Ramsay Santé, Institut Cardiovasculaire Paris Sud, Hôpital Privé Jacques-Cartier, Massy, France.
  • Leipsic JA; Department of Cardiology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Blanke P; Centre for Cardiovascular Innovation, St Paul's and Vancouver General Hospital, Vancouver, Canada.
  • Wood DA; Cardiovascular Translational Laboratory, Providence Research & Centre for Heart Lung Innovation, Vancouver, Canada.
  • Sellers SL; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
  • Webb JG; Centre for Cardiovascular Innovation, St Paul's and Vancouver General Hospital, Vancouver, Canada.
  • Sathananthan J; Centre for Heart Valve Innovation, St. Paul's Hospital, University of British Columbia, 1081 Burrard Street, Vancouver, BC, V6Z 1Y6, Canada.
Curr Cardiol Rep ; 25(11): 1425-1431, 2023 11.
Article in En | MEDLINE | ID: mdl-37815660
PURPOSE OF REVIEW: As TAVR is increasingly performed on younger patients with a longer life expectancy, the number of redo-TAVR procedures is likely to increase in the coming years. Limited data is currently available on this sometimes challenging procedure. We provide a summary of currently published literature on management of patients with a failed transcatheter aortic valve. RECENT FINDINGS: Recent registry data have increased the clinical knowledge on redo-TAVR. Additionally, numerous bench studies have provided valuable insights into the technical aspects of redo-TAVR with various combinations of valve types. Redo-TAVR can be performed safely in selected cases with a high procedural success and good short-term outcomes. However, at present, the procedure remains relatively infrequent and many patients are not eligible. Bench testing can be useful to understand important concepts such as valve expansion, neoskirt, leaflet overhang, and leaflet deflection as well as their potential clinical implications.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aortic Valve Stenosis / Heart Valve Prosthesis / Transcatheter Aortic Valve Replacement Limits: Humans Language: En Journal: Curr Cardiol Rep Journal subject: CARDIOLOGIA Year: 2023 Type: Article Affiliation country: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Aortic Valve Stenosis / Heart Valve Prosthesis / Transcatheter Aortic Valve Replacement Limits: Humans Language: En Journal: Curr Cardiol Rep Journal subject: CARDIOLOGIA Year: 2023 Type: Article Affiliation country: Switzerland